The development of erythropoietic agents in oncology

ISSN： 1472-8214

Source： Expert Opinion on Emerging Drugs, Vol.10, Iss.3, 2005-08, pp. : 553-567

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vascular-disrupting agents in oncology

By Mita Monica M Sargsyan Liza Mita Alain C Spear Matt

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 3, 2013-03 ,pp. : 317-328

Informa Healthcare

Access to resources Recommend Favorite

Erythropoiesis-Stimulating Agents in Oncology

By Glaspy John A.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 6, 2008-07 ,pp. : 565-575

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

EGFR-targeting agents in oncology

By Garofalo Sonia Rosa Roberta Bianco Roberto Tortora Giampaolo

Expert Opinion on Therapeutic Patents, Vol. 18, Iss. 8, 2008-08 ,pp. : 889-901

Informa Healthcare

Access to resources Recommend Favorite

Establishing an Anemia Clinic for Optimal Erythropoietic-Stimulating Agent Use in Hematology-Oncology Patients

By Gilreath Jeffrey A. Sageser Daniel S. Jorgenson James A. Rodgers George M.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 6, 2008-07 ,pp. : 577-584

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Development of PARP inhibitors in oncology

By Rodon Jordi Iniesta Maria D Papadopoulos Kyriakos

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 1, 2009-01 ,pp. : 31-43

Informa Healthcare

Access to resources Recommend Favorite